Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China
DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of pare...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2333098 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717013417558016 |
|---|---|
| author | Aodi Huang Xia Xu Lin Tang Lifang Huang Jun Li Xue Zhang Jiajie Liu Yang Zhou Bingling Zhang Lei Wang Qian Zhang Zemei Zhou Yu Wang Xiaoqi Wang Qianqian Liu Siyu Liu Zundong Yin Fuzhen Wang |
| author_facet | Aodi Huang Xia Xu Lin Tang Lifang Huang Jun Li Xue Zhang Jiajie Liu Yang Zhou Bingling Zhang Lei Wang Qian Zhang Zemei Zhou Yu Wang Xiaoqi Wang Qianqian Liu Siyu Liu Zundong Yin Fuzhen Wang |
| author_sort | Aodi Huang |
| collection | DOAJ |
| description | DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of parental acceptance and interest in hexavalent vaccines can help policy makers and manufacturers make decisions about entering the vaccine market and the immunization program in China. We measured parental acceptance and willingness-to-pay (WTP) for a hexavalent vaccine to provide such evidence. We conducted a cross-sectional survey of children’s caregivers in 16 vaccination clinics in seven cities in China and obtained information on socio-demographics, knowledge of disease, confidence in vaccines, previous vaccination experience, and acceptance of and WTP for hexavalent vaccine. Multivariate logistic regression was used to determine factors influencing acceptance, and multivariate tobit regression was used to identify factors impacting WTP. Between April 28 and June 30, 2023, a total of 581 parents of children aged 0–6 years participated in the survey; 435 (74.87%, 95% CI:71.3%−78.4%) parents indicated acceptance of hexavalent vaccine. Residence location, parents’ education level, experience paying for vaccination, and disease knowledge scores were key factors affecting parents’ choices for vaccination. Mean (SD) and median (IQR) willingness to pay for full 4-dose course vaccination were 2266.66 (1177.1) CNY and 2400 (1600–2800) CNY. Children’s age (p < .001), parents’ education level (p = .024), and perceived price barriers (p < .001) were significantly associated with WTP. Parents have high acceptance and willingness to pay for hexavalent vaccine. The less money parents have to pay out of pocket, the more willing they can be to accept the vaccine. Therefore, acceptance may increase even further if the vaccine is covered by medical insurance, provided free of charge by the government, or if its price is reduced. Our results provide reference for optimizing and adjusting immunization strategies in China. |
| format | Article |
| id | doaj-art-8b2e648cc5ad4526b0a57f40458664c3 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-8b2e648cc5ad4526b0a57f40458664c32025-08-20T03:12:47ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2333098Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in ChinaAodi Huang0Xia Xu1Lin Tang2Lifang Huang3Jun Li4Xue Zhang5Jiajie Liu6Yang Zhou7Bingling Zhang8Lei Wang9Qian Zhang10Zemei Zhou11Yu Wang12Xiaoqi Wang13Qianqian Liu14Siyu Liu15Zundong Yin16Fuzhen Wang17National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaDepartment of National Immunization Programe, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, ChinaDepartment of National Immunization Programe, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaDepartment of National Immunization Programe, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, ChinaDepartment of National Immunization Programe, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, ChinaDepartment of National Immunization Programe, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, ChinaDepartment of National Immunization Programe, Hubei Provincial Center for Disease Control and Prevention, Wuhan, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaDTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of parental acceptance and interest in hexavalent vaccines can help policy makers and manufacturers make decisions about entering the vaccine market and the immunization program in China. We measured parental acceptance and willingness-to-pay (WTP) for a hexavalent vaccine to provide such evidence. We conducted a cross-sectional survey of children’s caregivers in 16 vaccination clinics in seven cities in China and obtained information on socio-demographics, knowledge of disease, confidence in vaccines, previous vaccination experience, and acceptance of and WTP for hexavalent vaccine. Multivariate logistic regression was used to determine factors influencing acceptance, and multivariate tobit regression was used to identify factors impacting WTP. Between April 28 and June 30, 2023, a total of 581 parents of children aged 0–6 years participated in the survey; 435 (74.87%, 95% CI:71.3%−78.4%) parents indicated acceptance of hexavalent vaccine. Residence location, parents’ education level, experience paying for vaccination, and disease knowledge scores were key factors affecting parents’ choices for vaccination. Mean (SD) and median (IQR) willingness to pay for full 4-dose course vaccination were 2266.66 (1177.1) CNY and 2400 (1600–2800) CNY. Children’s age (p < .001), parents’ education level (p = .024), and perceived price barriers (p < .001) were significantly associated with WTP. Parents have high acceptance and willingness to pay for hexavalent vaccine. The less money parents have to pay out of pocket, the more willing they can be to accept the vaccine. Therefore, acceptance may increase even further if the vaccine is covered by medical insurance, provided free of charge by the government, or if its price is reduced. Our results provide reference for optimizing and adjusting immunization strategies in China.https://www.tandfonline.com/doi/10.1080/21645515.2024.2333098Hexavalent vaccinecombination vaccinevaccine acceptancewillingness to paypayment card method |
| spellingShingle | Aodi Huang Xia Xu Lin Tang Lifang Huang Jun Li Xue Zhang Jiajie Liu Yang Zhou Bingling Zhang Lei Wang Qian Zhang Zemei Zhou Yu Wang Xiaoqi Wang Qianqian Liu Siyu Liu Zundong Yin Fuzhen Wang Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China Human Vaccines & Immunotherapeutics Hexavalent vaccine combination vaccine vaccine acceptance willingness to pay payment card method |
| title | Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China |
| title_full | Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China |
| title_fullStr | Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China |
| title_full_unstemmed | Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China |
| title_short | Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China |
| title_sort | acceptance and willingness to pay for dtap hbv ipv hib hexavalent vaccine among parents a cross sectional survey in china |
| topic | Hexavalent vaccine combination vaccine vaccine acceptance willingness to pay payment card method |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2333098 |
| work_keys_str_mv | AT aodihuang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT xiaxu acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT lintang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT lifanghuang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT junli acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT xuezhang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT jiajieliu acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT yangzhou acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT binglingzhang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT leiwang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT qianzhang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT zemeizhou acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT yuwang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT xiaoqiwang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT qianqianliu acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT siyuliu acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT zundongyin acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina AT fuzhenwang acceptanceandwillingnesstopayfordtaphbvipvhibhexavalentvaccineamongparentsacrosssectionalsurveyinchina |